{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:53:51Z","timestamp":1792616031175,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>FGFR2 is a therapy-relevant target in tumors of the upper gastrointestinal tract (GIT), and clinical trials are currently underway to test the efficacy of FGFR2 inhibitors. Tumor heterogeneity is one of the relevant causes of treatment failure. Almost nothing is known about the heterogeneous distribution of <jats:italic>FGFR2<\/jats:italic>-amplified clones in adenocarcinomas of the upper GIT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>To assess <jats:italic>FGFR2<\/jats:italic> gene copy number alteration and intratumoral heterogeneity of upper GIT adenocarcinomas, we analyzed 893 patient-derived formalin-fixed paraffin-embedded tumor specimens, including primary operated and neoadjuvant-treated tumors (462 gastric carcinomas and 429 esophageal adenocarcinomas) as well as complementary lymph node and distant metastasis by fluorescence in situ hybridization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-six gastric tumors (5.6%) and 21 esophageal adenocarcinomas (4.9%) showed <jats:italic>FGFR2<\/jats:italic> amplification. Overall, 93% of gastric carcinomas and 83% of esophageal carcinomas showed heterogeneous amplification. <jats:italic>FGFR2<\/jats:italic> amplification was found in different histological growth patterns, including intestinal and diffuse type according to the Lauren classification. In the primary gastric carcinoma group, <jats:italic>FGFR2<\/jats:italic> amplification was associated with poor prognosis (<jats:italic>p<\/jats:italic>\u2009=\u20090.005).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Homogeneous <jats:italic>FGFR2<\/jats:italic> amplification in tumors of the upper GIT is the exception. This has highly relevant implications in the nature of FGFR2 diagnostics (sufficient tumor cell number, determination of amplification at metastasis versus primary tumor, etc.) and on the response probability of appropriate inhibitors. It is relevant that the often poorly treatable and aggressive subtype of diffuse carcinomas (poorly cohesive carcinomas) also shows <jats:italic>FGFR<\/jats:italic>2 amplification and that an individualized therapy option with FGFR2 inhibitors could be an option in this group.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04460-w","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T18:57:39Z","timestamp":1669229859000},"page":"5289-5300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract"],"prefix":"10.1007","volume":"149","author":[{"given":"Jan","family":"Albin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Fahrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Siemanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rehkaemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Buettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane Josephine","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Alakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Hieggelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"4460_CR1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","volume":"29","author":"S Ahn","year":"2016","unstructured":"Ahn S, Lee J, Hong M et al (2016) FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol 29:1095\u20131103","journal-title":"Mod Pathol"},{"key":"4460_CR2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"4460_CR3","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2217\/fon-2019-0141","volume":"15","author":"DV Catenacci","year":"2019","unstructured":"Catenacci DV, Tesfaye A, Tejani M et al (2019) Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol 15:2073\u20132082","journal-title":"Future Oncol"},{"key":"4460_CR4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M et al (2015) Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 21:449\u2013456","journal-title":"Nat Med"},{"key":"4460_CR5","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00432-020-03295-7","volume":"146","author":"F Gebauer","year":"2020","unstructured":"Gebauer F, Kr\u00e4mer M, Bruns C et al (2020) Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma. J Cancer Res Clin Oncol 146:2319\u20132327","journal-title":"J Cancer Res Clin Oncol"},{"key":"4460_CR6","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1158\/1538-7445.AM2014-5446","volume":"74","author":"AT Gemo","year":"2014","unstructured":"Gemo AT, Deshpande AM, Palencia S et al (2014) Abstract 5446: FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification. Can Res 74:5446\u20135446","journal-title":"Can Res"},{"key":"4460_CR7","first-page":"57","volume":"32","author":"H Grabsch","year":"2010","unstructured":"Grabsch H, Sivakumar S, Gray S et al (2010) HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value\u2014conclusions from 924 cases of two independent series. Cell Oncol 32:57\u201365","journal-title":"Cell Oncol"},{"key":"4460_CR8","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.3748\/wjg.v22.i26.5879","volume":"22","author":"F Grillo","year":"2016","unstructured":"Grillo F, Fassan M, Sarocchi F et al (2016) HER2 heterogeneity in gastric\/gastroesophageal cancers: from benchside to practice. World J Gastroenterol 22:5879\u20135887","journal-title":"World J Gastroenterol"},{"key":"4460_CR9","first-page":"3893","volume":"11","author":"W Gu","year":"2021","unstructured":"Gu W, Yang J, Wang Y et al (2021) Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing. Am J Cancer Res 11:3893\u20133906","journal-title":"Am J Cancer Res"},{"key":"4460_CR10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1524-4741.2007.00396.x","volume":"13","author":"W Hanna","year":"2007","unstructured":"Hanna W, Nofech-Mozes S, Kahn HJ (2007) Intratumoral heterogeneity of HER2\/neu in breast cancer\u2014a rare event. Breast J 13:122\u2013129","journal-title":"Breast J"},{"key":"4460_CR11","doi-asserted-by":"crossref","first-page":"21763","DOI":"10.18632\/oncotarget.7845","volume":"7","author":"D Helbig","year":"2016","unstructured":"Helbig D, Ihle MA, P\u00fctz K et al (2016) Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget 7:21763\u201321774","journal-title":"Oncotarget"},{"key":"4460_CR12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.sla.0000245847.40779.10","volume":"245","author":"AH Holscher","year":"2007","unstructured":"Holscher AH, Schneider PM, Gutschow C, Schroder W (2007) Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg 245:241\u2013246","journal-title":"Ann Surg"},{"key":"4460_CR13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-017-4453-8","volume":"166","author":"Y Hou","year":"2017","unstructured":"Hou Y, Nitta H, Wei L et al (2017) HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Res Treat 166:447\u2013457","journal-title":"Breast Cancer Res Treat"},{"key":"4460_CR14","doi-asserted-by":"crossref","first-page":"152878","DOI":"10.1016\/j.prp.2020.152878","volume":"216","author":"JY Hur","year":"2020","unstructured":"Hur JY, Chao J, Kim K et al (2020) High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathol Res Pract 216:152878","journal-title":"Pathol Res Pract"},{"key":"4460_CR15","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1634\/theoncologist.2019-0121","volume":"24","author":"SJ Klempner","year":"2019","unstructured":"Klempner SJ, Madison R, Pujara V et al (2019) FGFR2-Altered gastroesophageal adenocarcinomas are an uncommon clinicopathologic entity with a distinct genomic landscape. Oncologist 24:1462\u20131468","journal-title":"Oncologist"},{"key":"4460_CR16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10120-017-0758-x","volume":"21","author":"Y Kuboki","year":"2018","unstructured":"Kuboki Y, Schatz CA, Koechert K et al (2018) In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients. Gastric Cancer 21:401\u2013412","journal-title":"Gastric Cancer"},{"key":"4460_CR17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/1535-7163.MCT-17-0367","volume":"17","author":"WM Lau","year":"2018","unstructured":"Lau WM, Teng E, Huang KK et al (2018) Acquired resistance to FGFR inhibitor in diffuse-type gastric cancer through an AKT-independent PKC-mediated phosphorylation of GSK3\u03b2. Mol Cancer Ther 17:232\u2013242","journal-title":"Mol Cancer Ther"},{"key":"4460_CR18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3892\/mco.2017.1194","volume":"6","author":"H Loeser","year":"2017","unstructured":"Loeser H, Waldschmidt D, Kuetting F et al (2017) Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target. Mol Clin Oncol 6:639\u2013642","journal-title":"Mol Clin Oncol"},{"key":"4460_CR19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00432-017-2374-x","volume":"143","author":"F Lordick","year":"2017","unstructured":"Lordick F, Al-Batran SE, Dietel M et al (2017) HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol 143:835\u2013841","journal-title":"J Cancer Res Clin Oncol"},{"key":"4460_CR20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/bjc.2011.603","volume":"106","author":"K Matsumoto","year":"2012","unstructured":"Matsumoto K, Arao T, Hamaguchi T et al (2012) FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 106:727\u2013732","journal-title":"Br J Cancer"},{"key":"4460_CR21","doi-asserted-by":"crossref","first-page":"175883592093788","DOI":"10.1177\/1758835920937889","volume":"12","author":"V Merz","year":"2020","unstructured":"Merz V, Zecchetto C, Simionato F et al (2020) A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction\/gastric cancer trastuzumab resistant: the FiGhTeR trial. Ther Adv Med Oncol 12:1758835920937889","journal-title":"Ther Adv Med Oncol"},{"key":"4460_CR22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1073\/pnas.89.1.246","volume":"89","author":"T Miki","year":"1992","unstructured":"Miki T, Bottaro DP, Fleming TP et al (1992) Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci U S A 89:246\u2013250","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4460_CR23","first-page":"42","volume":"4","author":"CC O'Sullivan","year":"2014","unstructured":"O\u2019Sullivan CC, Moon DH, Kohn EC, Lee JM (2014) Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid Tumors. Front Oncol 4:42","journal-title":"Front Oncol"},{"key":"4460_CR24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","volume":"8","author":"E Pectasides","year":"2018","unstructured":"Pectasides E, Stachler MD, Derks S et al (2018) Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov 8:37\u201348","journal-title":"Cancer Discov"},{"key":"4460_CR25","doi-asserted-by":"crossref","first-page":"e15074","DOI":"10.1200\/jco.2014.32.15_suppl.e15074","volume":"32","author":"KL Pierce","year":"2014","unstructured":"Pierce KL, Deshpande AM, Stohr BA et al (2014) FPA144, a humanized monoclonal antibody for both FGFR2-amplified and nonamplified, FGFR2b-overexpressing gastric cancer patients. J Clin Oncol 32:e15074\u2013e15074","journal-title":"J Clin Oncol"},{"key":"4460_CR26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10120-021-01197-2","volume":"24","author":"A Quaas","year":"2021","unstructured":"Quaas A, Pamuk A, Klein S et al (2021) Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma. Gastric Cancer 24:1213\u20131226","journal-title":"Gastric Cancer"},{"key":"4460_CR27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J Ruschoff","year":"2012","unstructured":"Ruschoff J, Hanna W, Bilous M et al (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25:637\u2013650","journal-title":"Mod Pathol"},{"key":"4460_CR28","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/SLA.0b013e31818f3afb","volume":"248","author":"PM Schneider","year":"2008","unstructured":"Schneider PM, Metzger R, Schaefer H et al (2008) Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 248:902\u2013908","journal-title":"Ann Surg"},{"key":"4460_CR29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10120-021-01195-4","volume":"24","author":"B Schoemig-Markiefka","year":"2021","unstructured":"Schoemig-Markiefka B, Eschbach J, Scheel AH et al (2021) Optimized PD-L1 scoring of gastric cancer. Gastric Cancer 24:1115\u20131122","journal-title":"Gastric Cancer"},{"key":"4460_CR30","doi-asserted-by":"crossref","first-page":"e0264011","DOI":"10.1371\/journal.pone.0264011","volume":"17","author":"T Schrumpf","year":"2022","unstructured":"Schrumpf T, Behrens HM, Haag J et al (2022) FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort. PLoS ONE 17:e0264011","journal-title":"PLoS ONE"},{"key":"4460_CR31","first-page":"5055","volume":"35","author":"H Shoji","year":"2015","unstructured":"Shoji H, Yamada Y, Okita N et al (2015) Amplification of FGFR2 gene in patients with advanced gastric cancer receiving chemotherapy: prevalence and prognostic significance. Anticancer Res 35:5055\u20135061","journal-title":"Anticancer Res"},{"key":"4460_CR32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2144\/04361RV01","volume":"36","author":"R Simon","year":"2004","unstructured":"Simon R, Mirlacher M, Sauter G (2004) Tissue microarrays. Biotechniques 36:98\u2013105","journal-title":"Biotechniques"},{"key":"4460_CR33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"4460_CR34","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A et al (2017) Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol 18:640\u2013653","journal-title":"Lancet Oncol"},{"key":"4460_CR35","doi-asserted-by":"crossref","first-page":"19748","DOI":"10.18632\/oncotarget.7782","volume":"7","author":"R Tokunaga","year":"2016","unstructured":"Tokunaga R, Imamura Y, Nakamura K et al (2016) Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget 7:19748\u201319761","journal-title":"Oncotarget"},{"key":"4460_CR36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116\u2013129","journal-title":"Nat Rev Cancer"},{"key":"4460_CR37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-Yi F et al (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476\u2013484","journal-title":"Gastric Cancer"},{"key":"4460_CR38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2021.39.3_suppl.160","volume":"39","author":"ZA Wainberg","year":"2021","unstructured":"Wainberg ZA, Enzinger PC, Kang Y-K et al (2021) Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric\/gastroesophageal junction adenocarcinoma (FIGHT). J Clin Oncol 39:160\u2013160","journal-title":"J Clin Oncol"},{"key":"4460_CR39","doi-asserted-by":"crossref","first-page":"e0245488","DOI":"10.1371\/journal.pone.0245488","volume":"16","author":"K Wallander","year":"2021","unstructured":"Wallander K, Eisfeldt J, Lindblad M et al (2021) Cell-free tumour DNA analysis detects copy number alterations in gastro-oesophageal cancer patients. PLoS ONE 16:e0245488","journal-title":"PLoS ONE"},{"key":"4460_CR40","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41598-021-84107-x","volume":"11","author":"M Yashiro","year":"2021","unstructured":"Yashiro M, Kuroda K, Masuda G et al (2021) Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer. Sci Rep 11:4698","journal-title":"Sci Rep"},{"key":"4460_CR41","doi-asserted-by":"crossref","first-page":"e0143207","DOI":"10.1371\/journal.pone.0143207","volume":"10","author":"P Ye","year":"2015","unstructured":"Ye P, Zhang M, Fan S et al (2015) Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: optimizing personalized healthcare through innovative pathological and statistical analysis. PLoS ONE 10:e0143207","journal-title":"PLoS ONE"},{"key":"4460_CR42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.21037\/tgh.2019.08.05","volume":"4","author":"M Zubarayev","year":"2019","unstructured":"Zubarayev M, Min EK, Son T (2019) Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond. Transl Gastroenterol Hepatol 4:59","journal-title":"Transl Gastroenterol Hepatol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04460-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04460-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04460-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T14:19:55Z","timestamp":1689430795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04460-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4460"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04460-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"In vivo experiments were performed in accordance with FELASA recommendations and with the approval of the local ethics committee under 81\u201302.04.2018.A368. Patients gave their written consent to the usage of their tumor specimens and the objective of the project is primarily in the field of diagnostics and quality assurance, approval was obtained from the University of Cologne Ethics Committee (reference number: 13\u2013091 and 10\u2013242; Lehmann and Grass et al.).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}